Neurology:高甘油三酯血症对动脉粥样硬化性血栓性脑卒中患者预后的影响

2022-04-04 Naomi MedSci原创

颈部大动脉动脉粥样硬化性狭窄是缺血性卒中的常见原因。 高甘油三酯血症被认为促进动脉粥样硬化病理学,是一个重要的可改变的危险因素,促使动脉粥样硬化血栓性卒中患者的残余血管风险,即使在他汀治疗期间。

颈部大动脉动脉粥样硬化性狭窄是缺血性卒中的常见原因。动脉粥样硬化性血栓性卒中患者与其他亚型卒中患者相比,进一步发生血管事件的风险最高,高危患者的年度风险超过15% 。最近的临床试验表明,与常规治疗相比,动脉粥样硬化性血栓性卒中患者可能受益于更强烈的抗血小板疗法或更低的胆固醇低密度脂蛋白(ldl-c)靶向治疗。这意味着这个群体需要更好的、新颖的、量身定做的方法。

二级卒中预防的脂质管理主要目标是使用他汀类药物降低 ldl-c 水平。最近,高甘油三酯水平已成为动脉粥样硬化性心血管疾病的预测指标和新的治疗靶点。甘油三酯富含脂蛋白可进入动脉内膜,促进动脉粥样硬化进程,从而发展成为动脉粥样硬化血栓形成。虽然有相互矛盾的结果,但越来越多的证据表明,使用纤维蛋白或欧米伽 -3脂肪酸来降低甘油三酯的疗法,可能对心血管有潜在的益处。此外,一种新的化合物,可以更有效地降低 tg 水平比目前可用的试剂已经开发和测试,在正在进行的第三阶段试验。

高甘油三酯血症和动脉粥样硬化性血栓性卒中之间的关系研究很少,其预后作用尚不清楚。近日,有研究人员试图评估高甘油三酯血症对动脉粥样硬化性血栓性卒中患者残余心血管风险的影响。

东京女子医科大学卒中登记处是一个持续的前瞻性、观察性的登记处,其中870名急性缺血性卒中或短暂性脑缺血发作,在发病后一周内连续登记并随访一年。高甘油三酯血症定义为空腹血清甘油三酯≥150mg/dl。颈头动脉明显狭窄定义为50% 或更大的狭窄、闭塞。主要结果是主要的不良心血管事件,包括非致命性卒中、非致命性急性冠状动脉综合症和血管性死亡。

  • 870例患者(平均年龄70.1岁,男性60.9%)中有217例(24.9%)存在高甘油三酯血症。
  • 高甘油三酯水平与颅内动脉狭窄的发生率增加有显著相关,尤其是在前循环,而不是颅外动脉狭窄。
  • 即使调整了潜在的混杂因素,包括基线低密度脂蛋白胆固醇和他汀类药物的使用(调整后的危害比为2.46; 置信区间为95% ,1.62-3.74) ,高甘油三酯血症患者发生严重心血管不良事件的风险也高于那些没有发生此类事件的患者(年发生率为20.9% 对9.7% ; p < 0.001)。
  • 高甘油三酯血症患者血管事件发生的危险性高于非高甘油三酯血症患者(n = 174,年发生率35.1% 对14.2% ,p = 0.001) ,颅内动脉明显狭窄者(n = 247,年发生率29.9% 对14.7% ,p = 0.006) ,以及颅外动脉明显狭窄者狭窄(n = 123,年发病率23.0% ,9.4% ,p = 0.042)。
  • 与此相反,高甘油三酯血症并不能预测心源性栓塞性卒中患者的复发性血管事件(n = 221; 年发病率19.1% 对10.5% ; p = 0.18)。

高甘油三酯血症是一个重要的可改变的危险因素,促使动脉粥样硬化血栓性卒中患者的残余血管风险,即使在他汀治疗期间。

试验注册信息: 东京女子医科大学卒中登记处的注册 https://upload.umin.ac.jp 是 umin000031913。

这项研究提供了一级证据,证明在动脉粥样硬化血栓性卒中患者中,高甘油三酯血症与主要心血管事件的风险增加有关。

文献来源:Hoshino T, Ishizuka K, Toi S, et al. Prognostic Role of Hypertriglyceridemia in Patients With Stroke of Atherothrombotic Origin [published online ahead of print, 2022 Mar 16]. Neurology. 2022;10.1212/WNL.0000000000200112. doi:10.1212/WNL.0000000000200112

评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1720455, encodeId=7f391e2045599, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Aug 28 17:00:33 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078193, encodeId=b0a220e8193c7, content=<a href='/topic/show?id=53cb89101eb' target=_blank style='color:#2F92EE;'>#血栓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89101, encryptionId=53cb89101eb, topicName=血栓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Oct 27 14:00:33 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944745, encodeId=b5231944e4557, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Thu Dec 15 21:00:33 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692275, encodeId=2d2716922e5d7, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Apr 12 05:00:33 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001781, encodeId=9d662001e81a2, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 02 11:00:33 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654739, encodeId=e67f1654e39a7, content=<a href='/topic/show?id=edc610251468' target=_blank style='color:#2F92EE;'>#高甘油三酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102514, encryptionId=edc610251468, topicName=高甘油三酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a424532179, createdName=flyingeagle85, createdTime=Thu Jun 02 17:00:33 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804134, encodeId=7e58180413426, content=<a href='/topic/show?id=d1b2e630123' target=_blank style='color:#2F92EE;'>#粥样硬化性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76301, encryptionId=d1b2e630123, topicName=粥样硬化性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jul 10 20:00:33 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679182, encodeId=f3f616e918236, content=<a href='/topic/show?id=7a2684e600b' target=_blank style='color:#2F92EE;'>#脑卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84760, encryptionId=7a2684e600b, topicName=脑卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091e27733095, createdName=weihongyv, createdTime=Fri Jul 15 21:00:33 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208488, encodeId=00d71208488ea, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9d2233692, createdName=1212ba38m22暂无昵称, createdTime=Mon Apr 04 09:32:48 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207753, encodeId=3ed4120e75370, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ea35451111, createdName=ms4000002026468787, createdTime=Fri Apr 01 07:28:09 CST 2022, time=2022-04-01, status=1, ipAttribution=)]
    2022-08-28 wangyang7969
  2. [GetPortalCommentsPageByObjectIdResponse(id=1720455, encodeId=7f391e2045599, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Aug 28 17:00:33 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078193, encodeId=b0a220e8193c7, content=<a href='/topic/show?id=53cb89101eb' target=_blank style='color:#2F92EE;'>#血栓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89101, encryptionId=53cb89101eb, topicName=血栓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Oct 27 14:00:33 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944745, encodeId=b5231944e4557, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Thu Dec 15 21:00:33 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692275, encodeId=2d2716922e5d7, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Apr 12 05:00:33 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001781, encodeId=9d662001e81a2, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 02 11:00:33 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654739, encodeId=e67f1654e39a7, content=<a href='/topic/show?id=edc610251468' target=_blank style='color:#2F92EE;'>#高甘油三酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102514, encryptionId=edc610251468, topicName=高甘油三酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a424532179, createdName=flyingeagle85, createdTime=Thu Jun 02 17:00:33 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804134, encodeId=7e58180413426, content=<a href='/topic/show?id=d1b2e630123' target=_blank style='color:#2F92EE;'>#粥样硬化性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76301, encryptionId=d1b2e630123, topicName=粥样硬化性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jul 10 20:00:33 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679182, encodeId=f3f616e918236, content=<a href='/topic/show?id=7a2684e600b' target=_blank style='color:#2F92EE;'>#脑卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84760, encryptionId=7a2684e600b, topicName=脑卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091e27733095, createdName=weihongyv, createdTime=Fri Jul 15 21:00:33 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208488, encodeId=00d71208488ea, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9d2233692, createdName=1212ba38m22暂无昵称, createdTime=Mon Apr 04 09:32:48 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207753, encodeId=3ed4120e75370, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ea35451111, createdName=ms4000002026468787, createdTime=Fri Apr 01 07:28:09 CST 2022, time=2022-04-01, status=1, ipAttribution=)]
    2022-10-27 仁者大医
  3. [GetPortalCommentsPageByObjectIdResponse(id=1720455, encodeId=7f391e2045599, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Aug 28 17:00:33 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078193, encodeId=b0a220e8193c7, content=<a href='/topic/show?id=53cb89101eb' target=_blank style='color:#2F92EE;'>#血栓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89101, encryptionId=53cb89101eb, topicName=血栓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Oct 27 14:00:33 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944745, encodeId=b5231944e4557, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Thu Dec 15 21:00:33 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692275, encodeId=2d2716922e5d7, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Apr 12 05:00:33 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001781, encodeId=9d662001e81a2, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 02 11:00:33 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654739, encodeId=e67f1654e39a7, content=<a href='/topic/show?id=edc610251468' target=_blank style='color:#2F92EE;'>#高甘油三酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102514, encryptionId=edc610251468, topicName=高甘油三酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a424532179, createdName=flyingeagle85, createdTime=Thu Jun 02 17:00:33 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804134, encodeId=7e58180413426, content=<a href='/topic/show?id=d1b2e630123' target=_blank style='color:#2F92EE;'>#粥样硬化性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76301, encryptionId=d1b2e630123, topicName=粥样硬化性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jul 10 20:00:33 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679182, encodeId=f3f616e918236, content=<a href='/topic/show?id=7a2684e600b' target=_blank style='color:#2F92EE;'>#脑卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84760, encryptionId=7a2684e600b, topicName=脑卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091e27733095, createdName=weihongyv, createdTime=Fri Jul 15 21:00:33 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208488, encodeId=00d71208488ea, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9d2233692, createdName=1212ba38m22暂无昵称, createdTime=Mon Apr 04 09:32:48 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207753, encodeId=3ed4120e75370, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ea35451111, createdName=ms4000002026468787, createdTime=Fri Apr 01 07:28:09 CST 2022, time=2022-04-01, status=1, ipAttribution=)]
    2022-12-15 huangshifeng
  4. [GetPortalCommentsPageByObjectIdResponse(id=1720455, encodeId=7f391e2045599, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Aug 28 17:00:33 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078193, encodeId=b0a220e8193c7, content=<a href='/topic/show?id=53cb89101eb' target=_blank style='color:#2F92EE;'>#血栓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89101, encryptionId=53cb89101eb, topicName=血栓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Oct 27 14:00:33 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944745, encodeId=b5231944e4557, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Thu Dec 15 21:00:33 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692275, encodeId=2d2716922e5d7, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Apr 12 05:00:33 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001781, encodeId=9d662001e81a2, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 02 11:00:33 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654739, encodeId=e67f1654e39a7, content=<a href='/topic/show?id=edc610251468' target=_blank style='color:#2F92EE;'>#高甘油三酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102514, encryptionId=edc610251468, topicName=高甘油三酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a424532179, createdName=flyingeagle85, createdTime=Thu Jun 02 17:00:33 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804134, encodeId=7e58180413426, content=<a href='/topic/show?id=d1b2e630123' target=_blank style='color:#2F92EE;'>#粥样硬化性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76301, encryptionId=d1b2e630123, topicName=粥样硬化性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jul 10 20:00:33 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679182, encodeId=f3f616e918236, content=<a href='/topic/show?id=7a2684e600b' target=_blank style='color:#2F92EE;'>#脑卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84760, encryptionId=7a2684e600b, topicName=脑卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091e27733095, createdName=weihongyv, createdTime=Fri Jul 15 21:00:33 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208488, encodeId=00d71208488ea, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9d2233692, createdName=1212ba38m22暂无昵称, createdTime=Mon Apr 04 09:32:48 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207753, encodeId=3ed4120e75370, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ea35451111, createdName=ms4000002026468787, createdTime=Fri Apr 01 07:28:09 CST 2022, time=2022-04-01, status=1, ipAttribution=)]
    2022-04-12 bnurmamat
  5. [GetPortalCommentsPageByObjectIdResponse(id=1720455, encodeId=7f391e2045599, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Aug 28 17:00:33 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078193, encodeId=b0a220e8193c7, content=<a href='/topic/show?id=53cb89101eb' target=_blank style='color:#2F92EE;'>#血栓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89101, encryptionId=53cb89101eb, topicName=血栓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Oct 27 14:00:33 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944745, encodeId=b5231944e4557, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Thu Dec 15 21:00:33 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692275, encodeId=2d2716922e5d7, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Apr 12 05:00:33 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001781, encodeId=9d662001e81a2, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 02 11:00:33 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654739, encodeId=e67f1654e39a7, content=<a href='/topic/show?id=edc610251468' target=_blank style='color:#2F92EE;'>#高甘油三酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102514, encryptionId=edc610251468, topicName=高甘油三酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a424532179, createdName=flyingeagle85, createdTime=Thu Jun 02 17:00:33 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804134, encodeId=7e58180413426, content=<a href='/topic/show?id=d1b2e630123' target=_blank style='color:#2F92EE;'>#粥样硬化性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76301, encryptionId=d1b2e630123, topicName=粥样硬化性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jul 10 20:00:33 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679182, encodeId=f3f616e918236, content=<a href='/topic/show?id=7a2684e600b' target=_blank style='color:#2F92EE;'>#脑卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84760, encryptionId=7a2684e600b, topicName=脑卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091e27733095, createdName=weihongyv, createdTime=Fri Jul 15 21:00:33 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208488, encodeId=00d71208488ea, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9d2233692, createdName=1212ba38m22暂无昵称, createdTime=Mon Apr 04 09:32:48 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207753, encodeId=3ed4120e75370, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ea35451111, createdName=ms4000002026468787, createdTime=Fri Apr 01 07:28:09 CST 2022, time=2022-04-01, status=1, ipAttribution=)]
    2022-05-02 仁者大医

    #Neurol#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1720455, encodeId=7f391e2045599, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Aug 28 17:00:33 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078193, encodeId=b0a220e8193c7, content=<a href='/topic/show?id=53cb89101eb' target=_blank style='color:#2F92EE;'>#血栓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89101, encryptionId=53cb89101eb, topicName=血栓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Oct 27 14:00:33 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944745, encodeId=b5231944e4557, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Thu Dec 15 21:00:33 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692275, encodeId=2d2716922e5d7, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Apr 12 05:00:33 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001781, encodeId=9d662001e81a2, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 02 11:00:33 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654739, encodeId=e67f1654e39a7, content=<a href='/topic/show?id=edc610251468' target=_blank style='color:#2F92EE;'>#高甘油三酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102514, encryptionId=edc610251468, topicName=高甘油三酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a424532179, createdName=flyingeagle85, createdTime=Thu Jun 02 17:00:33 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804134, encodeId=7e58180413426, content=<a href='/topic/show?id=d1b2e630123' target=_blank style='color:#2F92EE;'>#粥样硬化性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76301, encryptionId=d1b2e630123, topicName=粥样硬化性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jul 10 20:00:33 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679182, encodeId=f3f616e918236, content=<a href='/topic/show?id=7a2684e600b' target=_blank style='color:#2F92EE;'>#脑卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84760, encryptionId=7a2684e600b, topicName=脑卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091e27733095, createdName=weihongyv, createdTime=Fri Jul 15 21:00:33 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208488, encodeId=00d71208488ea, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9d2233692, createdName=1212ba38m22暂无昵称, createdTime=Mon Apr 04 09:32:48 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207753, encodeId=3ed4120e75370, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ea35451111, createdName=ms4000002026468787, createdTime=Fri Apr 01 07:28:09 CST 2022, time=2022-04-01, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1720455, encodeId=7f391e2045599, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Aug 28 17:00:33 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078193, encodeId=b0a220e8193c7, content=<a href='/topic/show?id=53cb89101eb' target=_blank style='color:#2F92EE;'>#血栓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89101, encryptionId=53cb89101eb, topicName=血栓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Oct 27 14:00:33 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944745, encodeId=b5231944e4557, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Thu Dec 15 21:00:33 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692275, encodeId=2d2716922e5d7, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Apr 12 05:00:33 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001781, encodeId=9d662001e81a2, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 02 11:00:33 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654739, encodeId=e67f1654e39a7, content=<a href='/topic/show?id=edc610251468' target=_blank style='color:#2F92EE;'>#高甘油三酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102514, encryptionId=edc610251468, topicName=高甘油三酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a424532179, createdName=flyingeagle85, createdTime=Thu Jun 02 17:00:33 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804134, encodeId=7e58180413426, content=<a href='/topic/show?id=d1b2e630123' target=_blank style='color:#2F92EE;'>#粥样硬化性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76301, encryptionId=d1b2e630123, topicName=粥样硬化性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jul 10 20:00:33 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679182, encodeId=f3f616e918236, content=<a href='/topic/show?id=7a2684e600b' target=_blank style='color:#2F92EE;'>#脑卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84760, encryptionId=7a2684e600b, topicName=脑卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091e27733095, createdName=weihongyv, createdTime=Fri Jul 15 21:00:33 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208488, encodeId=00d71208488ea, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9d2233692, createdName=1212ba38m22暂无昵称, createdTime=Mon Apr 04 09:32:48 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207753, encodeId=3ed4120e75370, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ea35451111, createdName=ms4000002026468787, createdTime=Fri Apr 01 07:28:09 CST 2022, time=2022-04-01, status=1, ipAttribution=)]
    2022-07-10 heli0118
  8. [GetPortalCommentsPageByObjectIdResponse(id=1720455, encodeId=7f391e2045599, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Aug 28 17:00:33 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078193, encodeId=b0a220e8193c7, content=<a href='/topic/show?id=53cb89101eb' target=_blank style='color:#2F92EE;'>#血栓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89101, encryptionId=53cb89101eb, topicName=血栓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Oct 27 14:00:33 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944745, encodeId=b5231944e4557, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Thu Dec 15 21:00:33 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692275, encodeId=2d2716922e5d7, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Apr 12 05:00:33 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001781, encodeId=9d662001e81a2, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 02 11:00:33 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654739, encodeId=e67f1654e39a7, content=<a href='/topic/show?id=edc610251468' target=_blank style='color:#2F92EE;'>#高甘油三酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102514, encryptionId=edc610251468, topicName=高甘油三酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a424532179, createdName=flyingeagle85, createdTime=Thu Jun 02 17:00:33 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804134, encodeId=7e58180413426, content=<a href='/topic/show?id=d1b2e630123' target=_blank style='color:#2F92EE;'>#粥样硬化性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76301, encryptionId=d1b2e630123, topicName=粥样硬化性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jul 10 20:00:33 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679182, encodeId=f3f616e918236, content=<a href='/topic/show?id=7a2684e600b' target=_blank style='color:#2F92EE;'>#脑卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84760, encryptionId=7a2684e600b, topicName=脑卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091e27733095, createdName=weihongyv, createdTime=Fri Jul 15 21:00:33 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208488, encodeId=00d71208488ea, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9d2233692, createdName=1212ba38m22暂无昵称, createdTime=Mon Apr 04 09:32:48 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207753, encodeId=3ed4120e75370, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ea35451111, createdName=ms4000002026468787, createdTime=Fri Apr 01 07:28:09 CST 2022, time=2022-04-01, status=1, ipAttribution=)]
    2022-07-15 weihongyv
  9. [GetPortalCommentsPageByObjectIdResponse(id=1720455, encodeId=7f391e2045599, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Aug 28 17:00:33 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078193, encodeId=b0a220e8193c7, content=<a href='/topic/show?id=53cb89101eb' target=_blank style='color:#2F92EE;'>#血栓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89101, encryptionId=53cb89101eb, topicName=血栓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Oct 27 14:00:33 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944745, encodeId=b5231944e4557, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Thu Dec 15 21:00:33 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692275, encodeId=2d2716922e5d7, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Apr 12 05:00:33 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001781, encodeId=9d662001e81a2, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 02 11:00:33 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654739, encodeId=e67f1654e39a7, content=<a href='/topic/show?id=edc610251468' target=_blank style='color:#2F92EE;'>#高甘油三酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102514, encryptionId=edc610251468, topicName=高甘油三酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a424532179, createdName=flyingeagle85, createdTime=Thu Jun 02 17:00:33 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804134, encodeId=7e58180413426, content=<a href='/topic/show?id=d1b2e630123' target=_blank style='color:#2F92EE;'>#粥样硬化性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76301, encryptionId=d1b2e630123, topicName=粥样硬化性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jul 10 20:00:33 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679182, encodeId=f3f616e918236, content=<a href='/topic/show?id=7a2684e600b' target=_blank style='color:#2F92EE;'>#脑卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84760, encryptionId=7a2684e600b, topicName=脑卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091e27733095, createdName=weihongyv, createdTime=Fri Jul 15 21:00:33 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208488, encodeId=00d71208488ea, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9d2233692, createdName=1212ba38m22暂无昵称, createdTime=Mon Apr 04 09:32:48 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207753, encodeId=3ed4120e75370, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ea35451111, createdName=ms4000002026468787, createdTime=Fri Apr 01 07:28:09 CST 2022, time=2022-04-01, status=1, ipAttribution=)]
    2022-04-04 1212ba38m22暂无昵称

    学习了

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1720455, encodeId=7f391e2045599, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Aug 28 17:00:33 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078193, encodeId=b0a220e8193c7, content=<a href='/topic/show?id=53cb89101eb' target=_blank style='color:#2F92EE;'>#血栓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89101, encryptionId=53cb89101eb, topicName=血栓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Oct 27 14:00:33 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944745, encodeId=b5231944e4557, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Thu Dec 15 21:00:33 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692275, encodeId=2d2716922e5d7, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Apr 12 05:00:33 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001781, encodeId=9d662001e81a2, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 02 11:00:33 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654739, encodeId=e67f1654e39a7, content=<a href='/topic/show?id=edc610251468' target=_blank style='color:#2F92EE;'>#高甘油三酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102514, encryptionId=edc610251468, topicName=高甘油三酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a424532179, createdName=flyingeagle85, createdTime=Thu Jun 02 17:00:33 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804134, encodeId=7e58180413426, content=<a href='/topic/show?id=d1b2e630123' target=_blank style='color:#2F92EE;'>#粥样硬化性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76301, encryptionId=d1b2e630123, topicName=粥样硬化性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jul 10 20:00:33 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679182, encodeId=f3f616e918236, content=<a href='/topic/show?id=7a2684e600b' target=_blank style='color:#2F92EE;'>#脑卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84760, encryptionId=7a2684e600b, topicName=脑卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091e27733095, createdName=weihongyv, createdTime=Fri Jul 15 21:00:33 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208488, encodeId=00d71208488ea, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9d2233692, createdName=1212ba38m22暂无昵称, createdTime=Mon Apr 04 09:32:48 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207753, encodeId=3ed4120e75370, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ea35451111, createdName=ms4000002026468787, createdTime=Fri Apr 01 07:28:09 CST 2022, time=2022-04-01, status=1, ipAttribution=)]
    2022-04-01 ms4000002026468787

    学习了

    0

相关资讯

Nat Med:替西帕肽的心血管事件风险评估

与对照组相比,替西帕肽并未增加2型糖尿病参与者发生主要心血管事件的风险。

JACC:哈佛研究:每天一勺橄榄油,这些疾病远离你!

较高的橄榄油摄入量与较低的总死亡率和特定原因的死亡率有关。

EHJ:实锤了!戒烟,而不是少吸烟,才能减少中风和心梗风险!

戒烟,而不是减少吸烟,才能降低包括中风及心梗在内的心血管疾病风险。

Diabetologia:诊断为2型糖尿病后,10年内发生心血管疾病风险有多大?

CVD风险预测分数不能准确识别在10年的随访中出现CVD事件的2型糖尿病患者。所有22个被评估的模型都具有可比性和适度的鉴别能力。

JAHA:急性冠状动脉综合征后病情稳定患者的心血管事件和长期猝死风险

ACS后10天内病情稳定的患者仍存在发生猝死的长期风险,其中发生额外心血管事件的风险最大。这些结果细化了猝死的长期风险和风险影响因素,这可能有助于临床医生改善治疗的机会。

Cardiovasc Diabetol:这一部位脂肪越少,糖尿病患者发生心血管意外的风险越高!

左前降支周围脂肪组织大量减少与2型糖尿病患者的心血管事件风险增加显著相关

拓展阅读

JACC-BTS述评 | 编辑述评贾恩志教授团队PGAM5-ANGPTL3研究:巨噬细胞“脂炎轴”揭示动脉粥样硬化调控新机制

目前对于血管生成素样蛋白3 (ANGPTL3)在巨噬细胞中的调控机制,特别是其与磷酸甘油酸变位酶5 (PGAM5)的相互作用机制尚未完全阐明。

22年追踪数据:长期血脂高的人,后来都怎么样了?

新近发表于《欧洲心脏杂志》的一项研究,量化了青年期血脂累积暴露与中年后ASCVD的关联。结果显示,青年时期血脂异常对心血管的伤害会“秋后算账”。

Materials Today Bio 深圳市人民医院徐金锋、刘莹莹团队开发双靶向微泡精准抑制巨噬细胞端粒酶活性治疗动脉粥样硬化

本研究开发了一种双靶向微泡药物递送系统,该系统有效识别并靶向AS斑块区域的M1巨噬细胞,进行特异性药物递送。

Adv Mater:中国药科大学姜雷等团队研究发现巨噬细胞靶向纳米粒调节胆固醇稳态以治疗动脉粥样硬化

该研究提出了一种多价纳米平台(siTTENPs))进行动脉粥样硬化治疗。

J Clin Invest 山东大学齐鲁医院张澄/张猛教授团队发现E3泛素连接酶Listerin调控动脉粥样硬化进展的新机制

该研究首次阐明,E3泛素连接酶Listerin通过介导胆固醇外流关键转运蛋白ABCA1的泛素化修饰及稳定,正向调控巨噬细胞胆固醇外流能力,进而抑制泡沫细胞形成和动脉粥样硬化进展。

Arthritis Rheumatol:SLE患者动脉粥样硬化进展更快,持续控制心血管风险和病情缓解可显著减缓斑块发展

SLE患者动脉粥样硬化进展速度显著快于健康人群,但CVRF持续控制与DORIS缓解可有效减缓斑块进展。

高甘油三酯血症临床管理多学科专家共识

高甘油三酯血症临床管理多学科专家共识工作组 · 2023-06-26

高甘油三酯血症及其心血管风险管理专家共识

中国胆固醇教育计划委员会 · 2017-02-20